Insights
Search Results
Client Highlights
3.30.26
Firm Advises Pinnacle Medicines on Corporate and IP Matters Related to Oversubscribed $89 Million Series B Financing
On March 26, 2026, Pinnacle Medicines, a biotechnology company pioneering the development of oral peptide therapeutics using proprietary AI and physics-based platforms, announced the closing of an oversubscribed $89 million Series B financing. The round was co-led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investors including OrbiMed. Wilson Sonsini Goodrich & Rosati advised Pinnacle on corporate and IP matters related to the transaction.
Client Highlights
3.12.26
Firm Advises Day One on IP Matters Related to $2.5 Billion Acquisition by Servier
On March 6, 2026, Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. Wilson Sonsini Goodrich & Rosati advised Day One on IP matters related to the transaction.
Client Highlights
3.09.26
Wilson Sonsini Advises Lead Investor on SHINE’s $240 Million Equity Funding
On February 27, 2026, SHINE Technologies, a nuclear fusion company, announced it has raised $240 million in equity funding led by NantWorks founder Dr. Patrick Soon-Shiong, with additional participation from Fidelity Management & Research Company, Sumitomo Corporation of Americas, Pelican Energy Partners, Deerfield Management, Oaktree Capital Management, and other existing investors. Wilson Sonsini Goodrich & Rosati advised lead investor OZ Shine LLC—a new investment company led by Dr. Soon-Shiong—on the transaction.
Client Highlights
11.19.25
Wilson Sonsini Advises Day One on IP Matters Related to Acquisition of Mersana
On November 13, 2025, Day One Biopharmaceuticals (Day One), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced it has signed a definitive merger agreement to acquire Mersana Therapeutics (Mersana). Wilson Sonsini Goodrich & Rosati advised Day One on IP due diligence related to the transaction.
Client Highlights
10.24.25
Wilson Sonsini Advises Elevara Medicines on IP Matters Related to $70 Million Series A Financing
On October 22, 2025, Elevara Medicines (Elevara), a clinical-stage biotech developing therapies for rheumatoid arthritis and chronic inflammatory diseases, announced the close of a $70 million Series A financing. The round was co-led by Forbion and Sofinnova Partners, with participation from founding investor Monograph Capital. Wilson Sonsini Goodrich & Rosati advised Elevara on IP matters related to the transaction.
Client Highlights
6.17.25
Wilson Sonsini Advises Verve Therapeutics on IP Matters Related to Merger with Lilly
On June 17, 2025, Eli Lilly and Company and Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, announced a definitive agreement for Lilly to acquire Verve. Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on IP matters related to the transaction.
Client Highlights
5.12.25
Firm Advises Sirius Therapeutics on Patent Matters Related to $50 Million Series B2 Financing
On May 9, 2025, biotechnology company Sirius Therapeutics announced that it has successfully completed nearly $50 million Series B2 financing. A corporate venture capital firm led the financing round and was joined by new investor BioTrack Capital and existing investors OrbiMed, Creacion Ventures, and Hankang Capital. Wilson Sonsini Goodrich & Rosati advised Sirius Therapeutics on patent matters related to the transaction.
Client Highlights
2.19.25
Firm Advises Novo Holdings on Investment in Newleos Therapeutics’ $93.5 Million Series A
On February 13, 2025, Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, announced the closing of an oversubscribed $93.5 million Series A financing. The financing was led by Goldman Sachs Alternatives with participation from Novo Holdings A/S, Longwood Fund, DCVC Bio, and Arkin Bio Capital. Wilson Sonsini advised Novo Holdings A/S on the transaction.
Client Highlights
1.13.25
Firm Advises Insilico on Patent Matters Related to Exclusive Global License Agreement with Menarini Group
On January 10, 2025, leading international pharmaceutical and diagnostics company the Menarini Group and Stemline Therapeutics, Inc., a wholly owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology. Wilson Sonsini Goodrich & Rosati advised Insilico on patent matters related to the agreement.
Client Highlights
10.10.24
Wilson Sonsini Advises on Patent Matters Related to Verona’s FDA Approval
On June 26, 2024, Verona Pharma announced that the U.S. Food and Drug Administration approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. Wilson Sonsini Goodrich & Rosati advised Verona Pharma on patent matters.
Client Highlights
3.26.24
Wilson Sonsini Advises Loyal on Patent Matters Related to $45 Million Series B
On March 21, 2024, Loyal for Dogs (Loyal), a biotech company pioneering longevity drugs for dogs, announced the completion of a $45 million Series B funding round led by Bain Capital Ventures. Wilson Sonsini Goodrich & Rosati advised Loyal on patent matters related to the Series B and represents the company in patent strategy and prosecution matters.
Client Highlights
1.12.24
Firm Advises JIXING on Acquisition of BIIB131 from Biogen
On January 11, 2024, Ji Xing Pharmaceuticals (JIXING), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved patients with serious and life-threatening diseases, announced the acquisition of BIIB131 from Biogen for clinical development. Wilson Sonsini Goodrich & Rosati advised JIXING on the transaction.
BIIB131 is an investigational drug for acute ischemic stroke (AIS). Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit more patients over current standard of care by extending the otherwise short treatment window.
BIIB131 is an investigational drug for acute ischemic stroke (AIS). Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit more patients over current standard of care by extending the otherwise short treatment window.